[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-445783-105":59,"doc-detail-445783-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pd17-next-generation-sequencing-gene-panel-for-gastrointestinal-stromal-tumor-care","PD17 Next-Generation Sequencing Gene Panel For Gastrointestinal Stromal Tumor Care","","Assessment examines the clinical value of a next-generation sequencing (NGS) gene panel for managing gastrointestinal stromal tumor (GIST) in routine practice. The evaluation targets clinical utility, relevant somatic molecular alterations, and the panel’s role in therapeutic care. Evidence is drawn from a fast-track review of systematic literature and guidelines, evidence levels for molecular actionability, targeted reimbursement lists, compassionate use authorizations, and stakeholder input. Results support improved diagnostic performance and clinical utility through targeted therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pd17-next-generation-sequencing-gene-panel-for-gastrointestinal-stromal-tumor-care/445783/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pd17-next-generation-sequencing-gene-panel-for-gastrointestinal-stromal-tumor-care/445783.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the objective of the NGS gene panel assessment for GIST?","Question",{"text":112,"@type":113},"To determine the benefit of using an NGS gene panel for clinical management of GIST in routine practice, including its clinical utility and role in therapeutic care.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was diagnostic performance evaluated in the assessment?",{"text":117,"@type":113},"Evidence compared NGS gene panel testing with alternative methods, showing superior diagnostic performance for KIT and PDGFRA alterations versus Sanger sequencing, and for NTRK1/2/3 fusions versus immunohistochemistry.",{"name":119,"@type":110,"acceptedAnswer":120},"Which patients and gene scenarios were considered justified for funding by the French National Authority for Health?",{"text":121,"@type":113},"Funding was justified for KIT and PDGFRA in intermediate/high recurrence-risk locally advanced or metastatic GIST, and in suspected cases with inconclusive histology; and for NTRK1/2/3 in refractory or relapsed locally advanced or metastatic pediatric wild-type GIST.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},445783,1791207455,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?_k=1776742907772140068","PD16 Multicriteria Model For The Inclusion Of Oncologic Drugs In The Essential Medicines List: Insights From The Ecuadorian Experience  \nVictor Flores,  \nPaulina Quirola ([sylvia.quirola@msp.gob.ec](sylvia.quirola@msp.gob.ec)), Fernanda Parreño and Elizabeth Guambo  \nIntroduction: Including drugs in the National Essential Medicines List is a complex process that considers population, budget, and socioeconomic factors. In Ecuador, these decisions rely on efficacy and safety data from existing studies without estimating the real impact and clinical benefit of the drugs. This study proposed amulticriteria model using minimal clinically important difference (MCID) values to evaluate oncologic drugs for inclusion.  \nMethods: Safety and efficacy were assessed using MCID values for primary outcomes, incorporating measures such as overall survival (OS), disease-free survival (DFS), and complete remission, following the Magnitude of Clinical Benefit Scale(v1.1) ofthe European Society for Medical Oncology. Epidemiological and demographic data were obtained from the National Institute of Statistics and quality of life was evaluated using EuroQol-5D scores. Information on oncologic drugs and regulatory considerations was sourced from authoritative organizations. All parameters were systematically organized and weighted, ensuring the total criteria groups accounted for 100 percent.  \nResults: Seven criteria groups were established, each containing parameters evaluated on a scale from zero to five, designed to reward or penalize based on assessment goals. The groups were weighted from five to 30 percent to reflect their relative importance or impact on decision-making. The criteria and weights were as follows:(i) disease burden (30%); (ii) efficacy (30%); (iii) safety (15%);(iv) quality of life impact (5%); (v) availability and accessibility (5%); (vi) therapeutic alternatives and international recommendations (10%); and (vii) other important criteria (5%) . Consequently, scores were weighted differently across groups.  \nConclusions: Accurately estimating the impact of oncologic drugs is critically important for public health. Implementing this multicriteria model will provide a more efficient, objective, and systematic framework for evaluating the inclusion, modification, or exclusion of oncologic drugs with respect to the National Essential Medicines List. This approach enhances decision-making processes and ensures the optimal selection of anti-cancer therapies, ultimately improving patient outcomes and resource allocation in Ecuador.  \nPD17 Next-Generation Sequencing Gene Panel For Gastrointestinal Stromal Tumor Care  \nMarie Daclin ([m.daclin@has-sante.fr](m.daclin@has-sante.fr)), Denis-Jean David and Cédric Carbonneil  \nIntroduction: The objective of this assessment was to determine the benefit of using a next-generation sequencing (NGS) gene panel for the clinical management of gastrointestinal stromal tumor (GIST) among patients in routine clinical practice. The aim was to assess the clinical utility of this procedure, the somatic molecular alterations of specific interest, and to define its role in the therapeutic care of patients with GIST.  \nMethods: The method used for this fast-track assessment were based on: (i) a critical analysis of systematic reviews, meta-analyses, and clinical practice guidelines identified by a systematic literature search;  \n(ii) identification of the level of evidence of molecular alteration clinical actionability as set out by the European Society for Medical Oncology Scale, of targeted therapies included on the list of reimbursable drugs assessed by the French National Authority for Health, or drugs that have compassionate use authorizations issued by the French National Agency for Medicines and Health Products Safety; and (iii) stakeholder consultations and observations by public health institutions.  \nResults: Assessment ofthe evidence and data demonstrated that NGS gene panel testing has: (i) super","cbCaiqT3gKMvIxta","https://ap.wps.com/l/cbCaiqT3gKMvIxta","pdf",32425,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the objective of the NGS gene panel assessment for GIST?\",\"answer\":\"To determine the benefit of using an NGS gene panel for clinical management of GIST in routine practice, including its clinical utility and role in therapeutic care.\"},{\"question\":\"How was diagnostic performance evaluated in the assessment?\",\"answer\":\"Evidence compared NGS gene panel testing with alternative methods, showing superior diagnostic performance for KIT and PDGFRA alterations versus Sanger sequencing, and for NTRK1/2/3 fusions versus immunohistochemistry.\"},{\"question\":\"Which patients and gene scenarios were considered justified for funding by the French National Authority for Health?\",\"answer\":\"Funding was justified for KIT and PDGFRA in intermediate/high recurrence-risk locally advanced or metastatic GIST, and in suspected cases with inconclusive histology; and for NTRK1/2/3 in refractory or relapsed locally advanced or metastatic pediatric wild-type GIST.\"}]","PD17 Next-Generation Sequencing Gene Panel For Gastrointestinal Stromal Tumor Care | PDF",1790712686]